探索他类药物使用或HMG-CoA减少酶抑制与偏头痛之间的关联:系统性审查和元分析
Hamdy A Makhlouf1, Amr K Hassan2,3, Nereen A Almosilhy4
1Faculty of Medicine, Minia University, Minya, Egypt.
The journal of headache and pain
|February 3, 2025
概括
通过减少胆固醇和炎症,他类药物可能有助于预防偏头痛. 研究表明潜在的保护作用,减少偏头痛的频率和强度,尽管需要更多的研究.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 类他类药物 (3-基-3-甲基-谷氨基酶A减少酶抑制剂) 降低肝脏胆固醇,改善内皮功能,减少血管炎症.
- 新出现的证据表明,他类药物可能会降低偏头痛风险,并有助于症状管理,但缺乏确的数据.
研究的目的:
- 系统地调查他类药物使用与偏头痛预防之间的关联.
- 确定他类药物对偏头痛预防作用的性质和强度.
主要方法:
- 在PubMed,Scopus,Web of Science和Cochrane图书馆进行全面的系统搜索,直到2024年10月.
- 包括关于HMG-CoA减少酶基因,他类药物的使用以及偏头痛风险/疗效的研究.
- 孟德尔随机化,观察性研究和随机对照试验 (RCT) 的分析.
主要成果:
- 门德尔随机化研究将HMGCR基因表达与偏头痛风险增加联系在一起 (OR 1.381.55).
- 观察性研究表明,他类药物具有保护作用 (OR 0.730.94),降低了整体偏头痛风险,特别是在光环和更高的维生素D的情况下.
- 随机试验组的分析表明,与安慰剂相比,他类药物显著降低了每月偏头痛的频率 (MD= -3.16,p=0.02) 和强度.
结论:
- 类药物显示出作为心血管健康和神经疾病如偏头痛的双重目的治疗的前景.
- HMGCR基因与偏头痛风险之间的联系,以及他类药物的疗效,表明了新的预防途径.
- 需要进行更大,更长期的研究来证实这些发现,因为研究设计的可变性.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...